Insider filing
Traded Jul 16 · filed 4 days later
Compensation award — excluded from discretionary-purchase analysis.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
INTS · NASDAQ · Biological Products, (No Diagnostic Substances)
$2.67−0.40 (−13.03%)
Close of Nov 17, 2026, vs Nov 16 · end-of-day, not a live quote
Intensity Therapeutics (INTS) · oqro.io/stocks/INTS · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Including 12 routine filings (option exercises, tax withholding, grants, gifts). Open-market trades only
Insider filing
Traded Jul 16 · filed 4 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Jul 16 · filed 4 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Jul 16 · filed 4 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Jul 16 · filed 4 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Jul 16 · filed 4 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Jul 16 · filed 4 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Jul 16 · filed 4 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Jun 30 · filed 1 day later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Jun 30 · filed 1 day later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Mar 26 · filed 4 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Dec 31, 2025 · filed 5 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Dec 31, 2025 · filed 5 days later
Compensation award — excluded from discretionary-purchase analysis.
0 open-market purchases and 0 open-market sales by insiders of INTS between Feb 25, 2026 and today, placed against the company's last 4 earnings releases. The latest on file was filed Nov 5, 2026.
PurchaseSale30 days before a release30 days after
| Earnings release | 30 days before | On the day | 30 days after |
|---|---|---|---|
| Nov 5, 2026 | None | None | None |
| Aug 11, 2026 | None | None | None |
| May 7, 2026 | None | None | None |
| Mar 27, 2026 | None | None | None |
Companies set trading windows, which usually close shortly before results and reopen after them, and insiders may trade under 10b5-1 plans adopted months earlier. A date alone does not show what a person knew or why they traded. Past release dates are the dates the company filed its 8-K with Item 2.02. An upcoming date, when one is mentioned, comes from the data provider's earnings calendar (Finnhub): it is not a company filing, it is not estimated by OQRO, and it may change. Open-market purchases and sales as reported on Form 4. Largest purchases around earnings, all companies